Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis' Zometa Adds Warning On Renal Safety

This article was originally published in The Pink Sheet Daily

Executive Summary

Revised labeling recommends dosing should be decreased for patients with mild-to-moderate renal impairment, based on the patient's creatinine clearance levels. Novartis recommends identification and management of "factors predisposing of renal deterioration."

You may also be interested in...

Zometa Label Adds Osteonecrosis Of The Jaw Precaution

Novartis sends "Dear Doctor" letter to notify oncologists, oral surgeons and urologists of the labeling change. The revised labeling recommends a dental examination prior to bisphosphonate treatment for at-risk patients.

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.

Changes To The NHS: How Can Pharma Best Position Itself?

The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts